- Trials with a EudraCT protocol (263)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
263 result(s) found for: Time constant.
Displaying page 1 of 14.
EudraCT Number: 2011-004253-11 | Sponsor Protocol Number: 1237.15 | Start Date*: 2012-01-11 | |||||||||||
Sponsor Name:Boehringer Ingelheim Finland Ky | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg, 5/5 µ... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) HU (Completed) ES (Completed) IE (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004660-30 | Sponsor Protocol Number: 1237.14 | Start Date*: 2012-01-18 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim b.v. | ||||||||||||||||||
Full Title: A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (F... | ||||||||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) DE (Completed) SE (Completed) AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004659-37 | Sponsor Protocol Number: 1237.13 | Start Date*: 2012-03-01 | ||||||||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm.V | ||||||||||||||||||
Full Title: A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (F... | ||||||||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) AT (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002590-10 | Sponsor Protocol Number: P130906 | Start Date*: 2016-02-11 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Effect of bronchodilators on effort induced dyspnoea in patients suffering lung hypertension | |||||||||||||
Medical condition: Idiopathic or heritable patients with pulmonary arterial hypertension (PAH). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003053-26 | Sponsor Protocol Number: TMC-BIV-05-01 | Start Date*: 2005-12-08 |
Sponsor Name:The Medicines Company UK Ltd | ||
Full Title: The ZBMUF trial: an open-label randomised study of the effects of ultra-filtration and high dose aprotinin on bivalirudin pharmacokinetics during and/or after cardiopulmonary bypass surgery | ||
Medical condition: This trial will involve approximately 42 patients requiring coronary artery bypass graft surgery (CABG). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-014416-35 | Sponsor Protocol Number: 1222.38 | Start Date*: 2010-01-22 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm.V | |||||||||||||
Full Title: Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5µg] and 10 µg [2 actuations... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014395-21 | Sponsor Protocol Number: 1222.37 | Start Date*: 2010-02-08 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002319-26 | Sponsor Protocol Number: D8830C00002 | Start Date*: 2005-12-20 |
Sponsor Name:AstraZeneca AB | ||
Full Title: Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study | ||
Medical condition: Crohn's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) AT (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003436-21 | Sponsor Protocol Number: D2450174 | Start Date*: 2005-10-26 | |||||||||||
Sponsor Name:Dainippon Sumitomo Pharma Europe Ltd | |||||||||||||
Full Title: A phase 2, multi-centre, randomised, double blind, placebo controlled study evaluating the efficacy, safety and pharmacokinetics of two doses of a candidate Disease Modifying Anti-Rheumatic Drug (D... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001589-17 | Sponsor Protocol Number: KN 38-7271-001 | Start Date*: Information not available in EudraCT |
Sponsor Name:KeyNeurotek Pharmaceuticals AG | ||
Full Title: A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic b... | ||
Medical condition: Comatose patients with traumatic brain injury (TBI). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004460-19 | Sponsor Protocol Number: P1604GTN | Start Date*: 2017-04-20 | |||||||||||
Sponsor Name:G. Pohl-Boskamp GmbH & Co.KG | |||||||||||||
Full Title: A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in... | |||||||||||||
Medical condition: Peripheral arterial occlusive disease (PAOD, femoro-popliteal stenosis) and intermittent claudication (Fontaine stage IIb, pain-free walking distance < 200 m), lasting for at least 3 months to ensu... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017168-17 | Sponsor Protocol Number: GS-US-270-0101 | Start Date*: 2010-05-31 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients with Heart Failure with Preserved Ejection Fraction | |||||||||||||
Medical condition: Heart failure with Preserved Ejection Fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003399-38 | Sponsor Protocol Number: NN9535-4533 | Start Date*: 2020-08-28 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease | |||||||||||||
Medical condition: Peripheral arterial disease Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) HU (Completed) NO (Completed) BE (Completed) DK (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001601-23 | Sponsor Protocol Number: s63950 | Start Date*: 2020-06-18 |
Sponsor Name:University Hospitals of Leuven | ||
Full Title: Pharmacokinetics of apixaban in patients with short bowel syndrome requiring long term parenteral nutrition | ||
Medical condition: theoretically none (PK study), but drug is used for prevention or treatment of VTE | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000942-36 | Sponsor Protocol Number: IMI2-PainCare-BioPain-RCT1 | Start Date*: 2019-09-06 | |||||||||||
Sponsor Name:Aarhus University | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, cross-over, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processi... | |||||||||||||
Medical condition: Healthy volunteers (intended indication: pain) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DK (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004437-16 | Sponsor Protocol Number: tobra-02 | Start Date*: 2013-05-15 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Pharmacokinetic evaluation and tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis | ||
Medical condition: Bronchiectasis Lung infections | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-018010-18 | Sponsor Protocol Number: V1.0,29.11.2009 | Start Date*: 2010-07-02 |
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I,Abt. f. Infektionen u.Tropenmedizin | ||
Full Title: Multiple-dose Pharmacokinetics of Doripenem during continuous venovenous hemodiafiltration and molecular adsorbent recirculating system in ICU patients and during hemodialysis in longterm hemodialy... | ||
Medical condition: pharmacokinetics of Doripenem during CVVHDF(intensive care patients continuous venovenous haemodiafiltration), MARS(extracorporeal liver assist device, using a hollow fiber dialysis column in which... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001912-31 | Sponsor Protocol Number: 124/05/16 | Start Date*: 2019-12-09 |
Sponsor Name:UNIVERSITY MEDICAL CENTRE LJUBLJANA | ||
Full Title: Treatment of headache attributed to temporomandibular disorder with a flat plane occlusal splint and injections of botulinum toxin | ||
Medical condition: Headache attributed to temporomandibular disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003348-63 | Sponsor Protocol Number: CBPS804A2204 | Start Date*: 2013-02-09 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, placebo-controlled trial of BPS804 on safety and tolerability in patients with late-stage chronic kidney disease | ||
Medical condition: Patients with chronic kidney disease stage 5D (CKD-5D) and evidence of mineral and bone disorder as judged by low serum intact PTH levels according to KDIGO guidelines | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-003137-42 | Sponsor Protocol Number: EPIFLUX | Start Date*: 2020-04-10 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | ||
Full Title: Exploring P-glycoprotein-mediated efflux transport at the blood-brain barrier as a biomarker of drug-resistance in focal epilepsy | ||
Medical condition: Investigation in healthy volunteers and epilepsy patients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
